Biogen

BIIB

Market cap $28.3B

Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026 Transcript

Biogen NASDAQ: BIIB said data from its Phase 2 CELIA study of diranersen in early Alzheimer's disease provide proof of concept for the tau-targeting therapy, despite the trial not meeting its primary endpoint of demonstrating a predefined dose-response pattern.

BIIB secures FDA approval for Leqembi Iqlik, letting early Alzheimer's patients start with a weekly at-home autoinjector instead of biweekly IV infusions.

Biogen Inc. (NASDAQ:BIIB) on Tuesday said it will advance investigational Alzheimer's therapy diranersen into Phase 3 testing after new Phase 2 data showed the tau-targeting treatment slowed clinical decline while producing significant biomarker reductions.

Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial Setting TOKYO and CAMBRIDGE, Mass., July 14, 2026 /PRNewswire/ -- Eisai Co., Ltd.

The lowest dose of Biogen's anti-tau Alzheimer's drug diranersen, which missed its primary goal in a midstage ​trial, reduced cognitive decline in five of six Alzheimer's assessment tools and significantly cut levels of the toxic protein in the brain, researchers ‌reported on Tuesday.

Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over the course of 18 months.

CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced data from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer's disease. The data, presented at the Alzheimer's Association International Conference (AAIC) 2026, expand upon previously reported topline results and demonstrate a combination of meaningful clinical efficacy and robust biomarker effects, providing Phase 2 proof of concept for diranersen's tau-directed mechanism of action. Based on the growing and consistent body of evidence from the Phase 1b and Phase 2 studies, Biogen plans to advance diranersen into confirmatory Phase 3 development.1

LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose planned for late August 2026 TOKYO and CAMBRIDGE, Mass., July 13, 2026 /PRNewswire/ -- Eisai Co., Ltd.

The U.S. FDA on Monday approved an ​at-home starting dose of Eisai's and Biogen's Alzheimer's drug, ‌allowing some patients to begin therapy with injections administered by themselves or a caregiver.